Rising Biosciences, Inc. CEO Reassures Supply Chain Remains Strong
Back to Newsroom
Mentioned in this Article

Rising Biosciences, Inc. CEO Reassures Supply Chain Remains Strong

Wednesday, August 5, 2020 9:00 AM
Share this article now
Topic:
Company Update

SANDUSKY, OH / ACCESSWIRE / August 5, 2020 / Rising Biosciences, Inc. (OTC PINK:RBII) CEO Arthur Hall said that as the large disinfectant manufacturers are reporting supply chain problems, RBII has no similar issues and is meeting customers' needs.

"Other larger companies have reported their supply chains are stressed", said Hall. "This kind of news has understandably concerned our current and pending customers. Rising Biosciences is not experiencing supply issues. We are in full production in our Ohio facility, adding two additional lines there and also starting production soon in Florida. We are reassuring our customers that we don't expect any supply interruptions."

The company is currently in contract negotiations with a health care group with over 300 facilities and involved in talks with several grocery retailers.

"Being a smaller company gives us some rather distinct advantages", added Hall. "We can pivot easily and react faster, providing more immediate solutions in this challenging environment. This Covid-19 pandemic is a moving target, affecting our daily lives and posing uncertainties about the future, both short and long term. We are extremely confident in our ability to maintain current production levels and quickly ramp them up as demand warrants."

Hall also said having a stable supply chain is a valuable competitive edge. "While larger companies are trying to limit quantities, we can provide what the customer needs now."

About Rising Biosciences, Inc.
About Rising Biosciences Inc. - In addition to Oxi Thyme, RBII operates three distinct business units. The first business unit is a physicians practice management company focused on the proper use of cannabis for the treatment of chronic pain, opioid addiction, and terminal patients. The second business unit is a research and development company focusing on oral and topical pharmaceuticals within the strict standards set forward by the pharmaceutical compounding industry and the FDA. The third business unit offers cutting edge behavioral health medical treatment for substance addiction from branches throughout the Midwest.

Follow RBII on the NEW Twitter account and on Facebook for LIVE updates!

https://twitter.com/RisingBioscien1

https://www.facebook.com/RisingBioSciences/

Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFO:
For Investor Inquiries: [email protected]

SOURCE: Rising Biosciences, Inc.

Rising Biosciences, Inc.
Exchange:
Ticker:
OTC PINK
RBII
$0.0041
20.59%
Back to Newsroom
Copyright 2020 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: